Records containing: Melanoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-01-21A Phase I/Ib, Open-label, Multi-center, Study of DKY709 as a Single Agent and in Combination With PDR001 in Patients With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2026-01-21Novel RNA-lipid Particle (RNA-LP) Vaccine for Anti-PD-1 Antibody Therapy Sensitization
-
CLINICAL_TRIALS study record update · 2026-01-20Correlation Between Early Interval 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography (PET/CT) and Circulating Tumor DNA (ctDNA) in Advanced Melanoma Patients Treated With Immune Checkpoint Inhibitors
-
CLINICAL_TRIALS study record update · 2026-01-15Collection of Tissue, Blood and Other Specimens From Patients With Benign and Malignant Tumors of the Soft Tissue, Gastrointestinal Tract, and Other Intra-abdominal Sites.
-
CLINICAL_TRIALS study record update · 2026-01-15Sample Collection for Ongoing Research and Product Evaluation (SCORE) Study
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2026-01-14A Phase 1/2 Open-Label, Dose Finding and Expansion Study to Investigate the Safety and Effectiveness and Determination of the Optimal Dose of N17350 Administered Intratumorally in Participants With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2026-01-14QUILT-3.055: A Phase IIb, Multicohort, Open-Label Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With PD-1/PD-L1 Immune Checkpoint Inhibitors
-
CLINICAL_TRIALS study record update · 2026-01-12Long-term Safety Outcomes in Patients Treated With Replimune Oncolytic Immunotherapy Products
-
CLINICAL_TRIALS study record update · 2026-01-12Extended Follow-up of Patients With Melanoma Treated With Fianlimab Plus Cemiplimab in Expansion Cohorts From Study R3767-ONC-1613
-
CLINICAL_TRIALS study record update · 2026-01-12A Phase I/II, Open-label, Dose-escalation and Expansion Study to Assess the Safety, Pharmacokinetics and Clinical Activity of NUC-7738, a Nucleotide Analogue, in Patients With Advanced Solid Tumours and Lymphoma
-
CLINICAL_TRIALS study record update · 2026-01-12A Randomized, Double-Blind Study Evaluating the Efficacy, Safety, and Immunogenicity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Treatment-Naïve Unresectable or Metastatic Melanoma
-
CLINICAL_TRIALS study record update · 2026-01-08Phase I Randomized Open Label Trial Investigating Adoptive Transfer of CD39+CD103+CD8+ Tumor-isolated T Cells (AGX148) Alone or Combined With siRNA Modulation of PD-1 (AGX148/PH-762) in Patients With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2026-01-08A Randomized Study of Urolithin A vs. Placebo in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors
-
CLINICAL_TRIALS study record update · 2026-01-08Selection Pressure and Evolution Induced by Immune Checkpoint Inhibitors and Other Immunologic Therapies
-
CLINICAL_TRIALS study record update · 2026-01-08A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab + Relatlimab Fixed-dose Combination Versus Nivolumab Monotherapy After Complete Resection of Stage III-IV Melanoma
-
CLINICAL_TRIALS study record update · 2026-01-07Measuring Real Time Decision-Making About UVR Protection
-
CLINICAL_TRIALS study record update · 2026-01-07Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
-
CLINICAL_TRIALS study record update · 2026-01-05Phase II Randomized Controlled Trial of Biologically Guided Stereotactic Body Radiation Therapy in Oligoprogressive Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma
-
CLINICAL_TRIALS study record update · 2026-01-05A Phase II Study of the Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
-
CLINICAL_TRIALS study record update · 2025-12-30Contrast-enhanced Ultrasound for Sentinel Node Detection in Patients With Melanoma, Breast Cancer or Head & Neck Cancer
-
CLINICAL_TRIALS study record update · 2025-12-30Written Advice to Improve Compliance With Early Detection of Melanoma in First-degree Relatives: a Multicenter, Cluster-randomized Intervention Trial to Evaluate the Impact of Specific Incentives and Study Psychological Determinants of Early Melanoma Detection Behavior in First-degree Relatives
-
CLINICAL_TRIALS study record update · 2025-12-30A Clinical Performance Study to Validate the Use of Novel Molecular Diagnostic Assays for the Detection of Cancer Biomarkers in Peripheral Blood and Primary Tumor Tissue of Patients With Recurrent/Metastatic HNSCC, NSCLC or Melanoma.
-
CLINICAL_TRIALS study record update · 2025-12-29A Phase I Study With a Personalized NeoAntigen Cancer Vaccine in Melanoma
-
CLINICAL_TRIALS study record update · 2025-12-24Randomized Clinical Trial of a Telemedicine-mHealth Symptom Cluster Intervention for Advanced Cancer Patients: Increasing Access in Rural Areas
-
CLINICAL_TRIALS study record update · 2025-12-24A Phase 1/1b Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of KIN-2787 in Participants With BRAF and/or NRAS Mutation-positive Solid Tumors.